StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) bonds

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)

Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$2.57B
$5.96M due within a year
Net debt
$2.44B
After $127.64M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Notes and loans outstanding

As tagged in Amneal Pharmaceuticals's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issuedCarrying value
Term Loan 2028–2028$2.35B–
Term Loan Due 2028–2028–$0
Senior Notes Due 20326.88%2032$600.00M$600.00M
Term Loan Due 2032–2032–$2.08B
Amended New Revolving Credit Facility––$600.00M–
Rondo Term Loan––$180.00M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeAvailableDrawn
Amended New Revolving Credit Agreement$600.00M$595.20M–
Amended Rondo Revolving Credit Facility$42.00M$83.00M$0
Rondo Revolving Credit Facility$90.00M––
Senior Secured Credit Facility, Asset Backed Revolving Credit Facility$25.00M$25.00M–

See a number that looks wrong?